Citi kept a Buy rating on Qiagen (QGEN) with a $55 price target while adding an “upside 90-day short-term view” on the shares. Qiagen’s “pillars of growth and strong” margin opportunity should provide a compelling backdrop for investors given the current state of the tools space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Cautious Optimism for Qiagen Amidst Industry Challenges: Awaiting Long-term Growth Assurance
- Qiagen’s Strong Positioning and Growth Potential Earns Buy Rating from Analyst
- Qiagen Receives Notification of BlackRock’s Voting Rights
- Qiagen’s Voting Rights Announcement Highlights BlackRock’s Influence
- Qiagen Receives Significant Voting Rights Notification from AFM